Literature DB >> 12637338

Change in alpha1 HDL concentration predicts progression in coronary artery stenosis.

Bela F Asztalos1, Marcelo Batista, Katalin V Horvath, Caitlin E Cox, Gerard E Dallal, Josh S Morse, Greg B Brown, Ernst J Schaefer.   

Abstract

OBJECTIVE: We examined the effects of simvastatin-niacin and antioxidant vitamins on changes in high-density lipoprotein (HDL) subpopulations and alterations in coronary artery stenosis, as assessed by angiography. METHODS AND
RESULTS: Lipids, lipoproteins, and HDL particles were measured on and off treatment in 123 subjects of the HDL-Atherosclerosis Treatment Study. Patients were assigned to 4 treatment groups, simvastatin-niacin, simvastatin-niacin-antioxidant vitamins, antioxidant vitamins, and placebo. Subjects were followed for 3 years on treatment and then for 2 months off treatment. Simvastatin-niacin significantly increased the 2 large apoA-I-containing HDL subpopulations, alpha1 and prealpha1, and significantly decreased the 2 smallest particles, prebeta1 and alpha3, compared with values obtained from the same patients off treatment. Adding antioxidant vitamins to the lipid-modifying agents blunted these effects (not significant). A significant negative correlation (r=-0.235; P<0.01) between the changes in alpha1 HDL particle concentration and coronary artery stenosis was noted. Subjects in the third tertile (157% increase in alpha1) had no progression of stenosis in the 3-year follow-up period, whereas subjects in the first tertile (15% decrease in alpha1) had an average of 2.1% increase in stenosis.
CONCLUSIONS: Simvastatin-niacin therapy significantly increased the large apoA-I-containing alpha1 HDL particles. This increase was significantly associated with less progression of coronary stenosis even after adjusting for traditional risk factors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12637338     DOI: 10.1161/01.ATV.0000066133.32063.BB

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  35 in total

Review 1.  Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.

Authors:  Michael H Davidson
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 2.  High-density lipoprotein subfractions and risk of coronary artery disease.

Authors:  John Morgan; Christina Carey; Anne Lincoff; David Capuzzi
Journal:  Curr Atheroscler Rep       Date:  2004-09       Impact factor: 5.113

3.  An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice.

Authors:  Shu-Chen Lu; Larissa Atangan; Ki Won Kim; Michelle M Chen; Renee Komorowski; Carolyn Chu; Joon Han; Sylvia Hu; Wei Gu; Murielle Véniant; Minghan Wang
Journal:  J Lipid Res       Date:  2012-01-27       Impact factor: 5.922

4.  Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence.

Authors:  B Greg Brown; Xue-Qiao Zhao; Marian C Cheung
Journal:  J Clin Lipidol       Date:  2007-02-15       Impact factor: 4.766

5.  Short communication: effects of omega-3 fatty acids on triglycerides and high-density lipoprotein subprofiles in HIV-infected persons with hypertriglyceridemia.

Authors:  Anu Paranandi; Bela F Asztalos; Alexandra Mangili; Jefferey Kuvin; Jul Gerrior; Heidi Sheehan; Sally C Skinner; Alice M Tang; Christine A Wanke
Journal:  AIDS Res Hum Retroviruses       Date:  2014-08       Impact factor: 2.205

6.  Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study.

Authors:  Masumi Ai; Seiko Otokozawa; Bela F Asztalos; Yasuki Ito; Katsuyuki Nakajima; Charles C White; L Adrienne Cupples; Peter W Wilson; Ernst J Schaefer
Journal:  Clin Chem       Date:  2010-04-29       Impact factor: 8.327

7.  High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency.

Authors:  Mariko Tani; Katalin V Horvath; Benoit Lamarche; Patrick Couture; John R Burnett; Ernst J Schaefer; Bela F Asztalos
Journal:  Atherosclerosis       Date:  2016-08-20       Impact factor: 5.162

8.  Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome.

Authors:  K G Lagos; T D Filippatos; V Tsimihodimos; I F Gazi; C Rizos; A D Tselepis; D P Mikhailidis; Moses S Elisaf
Journal:  Lipids       Date:  2008-10-28       Impact factor: 1.880

9.  Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.

Authors:  Stefania Lamon-Fava; Margaret R Diffenderfer; P Hugh R Barrett; Aaron Buchsbaum; Mawuli Nyaku; Katalin V Horvath; Bela F Asztalos; Seiko Otokozawa; Masumi Ai; Nirupa R Matthan; Alice H Lichtenstein; Gregory G Dolnikowski; Ernst J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-19       Impact factor: 8.311

10.  Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.

Authors:  Bela F Asztalos; Dorothea Collins; Katalin V Horvath; Hanna E Bloomfield; Sander J Robins; Ernst J Schaefer
Journal:  Metabolism       Date:  2008-01       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.